3BBLACKBIO · NSE
3B Blackbio Dx Limited
₹1,319.3
+2.21% (+₹28.5)
Prev. close
₹1,290.8
Volume
6,766
Delivery %
72.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About 3B Blackbio Dx Limited
3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dhirendra Kuber Dubey
Headquarters
Bhopal
Employees
86
Website
3bblackbio.comExchange
View on NSE ↗Key stats
P/E ratio (TTM)
19.9
Dividend yield
0.39%
EPS (TTM)
₹66.35
Beta (5Y monthly)
0.43
Shares float
29.39 L
EPS · quarter ended Jun 2026
₹11.11
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹226.74 Cr | ₹80.65 Cr | ₹61.84 Cr | ₹74.12 Cr | ₹96.47 Cr | ₹141.92 Cr | |
| EBITDA | ₹152.88 Cr | ₹44.00 Cr | ₹36.37 Cr | ₹45.51 Cr | ₹65.19 Cr | ₹82.33 Cr |
| ₹113.87 Cr | ₹32.20 Cr | ₹25.94 Cr | ₹32.73 Cr | ₹47.69 Cr | ₹59.93 Cr | |
| Diluted EPS | ₹151.68 | ₹42.89 | ₹30.27 | ₹37.46 | ₹55.66 | ₹69.94 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹193.52 Cr | ₹192.09 Cr | ₹214.06 Cr | ₹248.10 Cr | ₹295.72 Cr | ₹378.00 Cr | |
| ₹2.00 Cr | ₹2.53 Cr | ₹2.03 Cr | ₹78.81 L | ₹30.69 L | ₹4.77 Cr | |
| Stockholders' equity | ₹124.56 Cr | ₹145.53 Cr | ₹193.26 Cr | ₹223.05 Cr | ₹268.42 Cr | ₹324.38 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹20.28 Cr | ₹26.95 Cr | ₹43.36 Cr | ₹52.48 Cr | |
| Investing cash flow | — | — | ₹14.73 Cr | ₹-20.32 Cr | ₹-33.85 Cr | ₹-23.59 Cr |
| — | — | ₹-5.01 Cr | ₹-3.63 Cr | ₹-3.22 Cr | ₹-52.44 L | |
| Capital expenditure | — | — | ₹-2.02 Cr | ₹-50.80 L | ₹-90.39 L | ₹-25.51 Cr |
| End cash position | — | — | ₹59.21 Cr | ₹62.15 Cr | ₹68.83 Cr | ₹100.62 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| 3B Blackbio Dx Limited | — | ₹1,290.8 | 20.4 | — | 18.5% | 0.01 | +47.1% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
3B Blackbio DX consolidated net profit declines 24.31% in the June 2026 quarter
Business Standard · 1 month ago